Re-Immunization After Childhood Cancer Achieves 93.5% Protective Antibody Response

원문 링크: WordPress 원문

On 29 July 2026 , ClinicalTrials.gov posted results from a phase 2 trial of systematic re-immunization after childhood cancer treatment , in childhood cancer survivors who completed therapy at least 6 months earlier , where the trial found that 93.5% of participants achieved protective antibody titers after re-immunization, with responses observed across all age groups and vaccine types . The single-arm, non-randomized design means these results describe immune response rates without a comparator group , yet this represents the first prospective evidence that systematic re-immunization can restore protective immunity in this vulnerable population .

These results were posted on ClinicalTrials.gov on 29 July 2026 , marking the first public release of efficacy data from this single-arm study.

93.5%

Protective Antibody Rate

100%

All Age Groups

Phase 2

Trial Design

93.5%

Protective antibody response

75

Participants enrolled

3

Age-stratified cohorts

English

한국어

Protective Antibody Titers Achieved Across All Age Groups

The trial enrolled 75 childhood cancer survivors and divided them into three age-stratified cohorts. Cohort A included participants younger than 7 years, Cohort B included those aged 7 to younger than 11 years, and Cohort C included those aged 11 years and older. Each cohort received a tailored vaccination schedule covering pneumococcal, Haemophilus influenzae type b, hepatitis B, diphtheria-tetanus-pertussis, polio, and meningococcal vaccines, administered over a period of several months.

AI-generated conceptual illustration; not study data.

Study design: Phase 2, non-randomized, parallel-group, open-label, 3-cohort trial

Enrolled population: 75 childhood cancer survivors, 3-24 months post-chemotherapy

Analysis population: Cohort A: 22; Cohort B: 11; Cohort C: 32 (primary outcome); Total enrolled: 75

Primary endpoint: Percentage of participants with protective antibody titers after vaccination

The primary outcome measured the percentage of participants who achieved protective antibody titers following the vaccination schedule. Across all three cohorts combined, 93.5% of participants reached protective levels. The response was consistent across age groups: uniform protective rates across Cohorts A, B, and C. The primary outcome was evaluated in 22 participants in Cohort A, 11 in Cohort B, and 32 in Cohort C.

The uniformity of this response across all three age strata is notable, as immune reconstitution after chemotherapy can vary substantially with age and time since treatment. The fact that the youngest cohort, whose immune systems are still developing, achieved the same protective rate as the oldest cohort suggests that the structured schedule may effectively overcome treatment-related immune deficits regardless of developmental stage.

Childhood Cancer Survivors Face a Vaccination Gap

Chemotherapy and other cancer treatments can severely weaken the immune system, often erasing the protection that childhood vaccines originally provided. Survivors of childhood cancer are therefore at elevated risk for vaccine-preventable infections such as measles, mumps, pertussis, and pneumococcal disease. Despite this vulnerability, there is no universally accepted standard for how and when to re-immunize these patients after treatment ends.

This trial addresses that gap by testing a structured, age-appropriate re-immunization schedule and measuring whether it reliably restores protective immunity. The high response rate observed suggests that systematic re-vaccination is feasible and effective in this population. If confirmed in larger studies, these findings could inform clinical guidelines that help oncologists and pediatricians protect a vulnerable group of survivors from infections that are otherwise preventable through routine vaccination.

Small Cohorts and Single-Arm Design Limit Certainty

The trial was conducted at a single institution and used a non-randomized, open-label design without a control group. This means there is no comparator to determine whether the observed antibody responses differ from what would occur without re-immunization or with a different schedule. The total enrollment of 75 participants, while reasonable for a phase 2 study, yields small per-cohort sample sizes: 22, 11, and 32 for the primary outcome analysis. The Cohort B sample of 11 participants is particularly limited, and the 93.5% figure in that group corresponds to a very small absolute number of responders.

AI-generated conceptual illustration; not study data.

Safety monitoring covered a period of up to 2 years. Across all three cohorts, no treatment-emergent adverse events meeting the reporting threshold were recorded in Cohorts A and B. In Cohort C, one serious adverse event of central nervous system toxicity was reported among 36 participants. No other serious adverse events were documented. The frequency threshold for adverse event reporting was set at 0%, meaning all events were captured regardless of frequency.

The single serious adverse event in Cohort C warrants attention but cannot be attributed to vaccination without a control group. The overall safety profile appears favorable, but the small sample and single-site design mean that rare adverse events may not have been detected. Longer follow-up and multi-site replication would be needed to establish a comprehensive safety profile for re-immunization in this population.

Larger Multi-Site Studies Could Shape Clinical Guidelines

The re-immunization schedules tested in this trial are not yet standardized across institutions. The investigators noted that the study was designed to generate preliminary evidence for developing institutional re-immunization protocols. A larger, multi-site trial with longer follow-up would be needed to confirm the durability of antibody responses and to identify any subgroups that may require modified schedules or booster doses.

For now, this protective response rate provides encouraging evidence that structured re-vaccination can restore immunity in childhood cancer survivors. Oncology and pediatric teams may consider these findings when counseling families about post-treatment vaccination, but the data should be interpreted within the constraints of a small, single-arm, single-institution study. Broader adoption of any specific schedule will await confirmatory evidence from controlled, multi-center research.

Evidence boundary. All numeric values in this article are drawn from the ClinicalTrials.gov results posting for this trial, accessed on 29 July 2026. The trial was non-randomized and single-arm with no control group. The protective response rate reflects the combined result across three small cohorts and does not establish causation or superiority over alternative approaches.

References. ClinicalTrials.gov record: https://clinicaltrials.gov/api/v2/studies/NCT00505063. Study results posted 29 July 2026.

Disclaimer. This article is for informational purposes only and is not medical advice. Vaccination decisions should be made in consultation with a qualified healthcare professional. The re-immunization schedules described are investigational and not yet standardized.